← Browse by Condition
Medical Condition
epithelial ovarian cancer
Total Trials
6
Recruiting Now
6
Trial Phases
Phase 1, Phase 2, Phase 1
NCT07480954 Phase 1, Phase 2
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Enrollment
36 pts
Location
China
Sponsor
Beijing Biotech
NCT06395519 Phase 1, Phase 2
Recruiting
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Enrollment
120 pts
Location
United States
Sponsor
858 Therapeutics, Inc.
NCT06386887
Recruiting
Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer
Enrollment
20 pts
Location
United States
Sponsor
Case Comprehensive Cancer Cent...
NCT04282044 Phase 1
Recruiting
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Enrollment
60 pts
Location
United States
Sponsor
BioEclipse Therapeutics
NCT04429542 Phase 1
Recruiting
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Enrollment
292 pts
Location
United States, Austr...
Sponsor
Bicara Therapeutics
NCT05200559 Phase 1, Phase 2
Recruiting
T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors
Enrollment
70 pts
Location
United States
Sponsor
Alexander B Olawaiye, MD